Part 1: background, methodology, and clinical adoption of pharmacogenetics. - Wikidata - awgldk - TriplyDB

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

http://www.wikidata.org/entity/Q37883726

about

Lung cancer biomarkers, targeted therapies and clinical assays Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?Clinically relevant cancer biomarkers and pharmacogenetic assays.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Application of genotype-guided cancer therapy in solid tumors.Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.SNPs and taxane toxicity in breast cancer patients.

P2860

Q26775396-16AB086B-CE10-4CFC-A958-003263D92EDD Q35981408-A01EEF51-D445-43A4-A619-B2467F17520B Q38077041-5468CEB7-1319-489B-A2DB-AE8047736442 Q38082728-63E59DE5-92BC-4456-872D-1844C6396CA8 Q38170457-003A7B75-BCEC-4EFC-859E-30925AAC2A1A Q41469853-2977BD1C-353F-462C-BD8D-D0D53DE00D47 Q46800256-219BF69D-3AAD-4D1C-9402-60C08C9D0124

P2860

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

http://www.wikidata.org/entity/Q37883726

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@en

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@nl

type

label

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@en

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@nl

prefLabel

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@en

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@nl

P1433

Q37883726-36BD07CF-3BE1-4A56-96B3-6CA418D832AE

P1476

Q37883726-E7A0369A-D60E-4C6E-BD8E-EA0DABE20A8F

P2093

Q37883726-5A7777FA-8F1A-4ED2-8EA6-9848F8717D56

Q37883726-5ECD5D69-6278-4388-81A2-ED5D9D4E1940

Q37883726-73E775F8-E4D5-49F4-B349-C6E9B505EE40

Q37883726-8FB18069-3F04-4162-96A4-635466A2534A

P2860

Q37883726-04994EC8-9188-4A14-A020-3C22E51F87B2

Q37883726-0D25A93B-BDED-44B2-A694-96D2A194FD20

Q37883726-0F8FE03F-C3F7-4CFA-AAD6-9F495E661708

Q37883726-14176DD9-F5C5-44A6-9177-BD76054ED576

Q37883726-1D1D4902-0E50-4A3C-9B56-A989A1BE94F5

Q37883726-2416D6F2-D464-49C3-A14F-04D828D0C5DC

Q37883726-26149FC7-9E89-44B3-A179-1E2F6CC81221

Q37883726-29448EC4-2472-46CA-8955-63F54FC591A1

Q37883726-2CF8EBA7-30C6-4E99-A98E-E4460061D5FE

Q37883726-2EBB7E8A-4A5D-47C1-8B1E-C3083DABEE58

P304

Q37883726-DD3B5551-8CF2-4FB5-843D-5B153EF0AFC2

P31

Q37883726-BF348AA1-39BF-4A52-A6CD-5FE3F0517AAF

P356

Q37883726-2FEC7BC5-3B23-4D9C-B04F-169122AC0930

P433

Q37883726-F704BA09-E083-4CB8-A22C-6A6DCDE65F58

P478

Q37883726-C0BD5736-1977-40E3-9BBF-64A7CC08B645

P577

Q37883726-93DAF8F2-D93E-4B09-A814-5015D8DA02B8

P5875

Q37883726-3BF8F87C-0316-435F-AF99-D5C38E8E2D10

P698

Q37883726-BE17734B-42BB-40CB-912E-94BAF6BCFC55

P932

Q37883726-0A102921-7667-4D14-A1C8-C45020AD20EC

P356

THEONCOLOGIST.2010-0258

P1433

P1476

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@en

P2093

Annemieke Cats

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Maarten J Deenen

http://www.w3.org/2001/XMLSchema#string

P2860

Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.

Global variation in copy number in the human genome

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

P304

811-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0258

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51183761

http://www.w3.org/2001/XMLSchema#string

P698

21632456

http://www.w3.org/2001/XMLSchema#string

P932

3228225

http://www.w3.org/2001/XMLSchema#string